Table 1.
Bcl-2-family targeting drugs
| Drug name | Drug class-mechanism of action | Drug targets | Stage of development | Ref (PMID #) |
|---|---|---|---|---|
| Cyclin-dependent kinase inhibitor | Flavopiridol | Cyclin dependent kinases and Mcl-1 | Clinical trials | 22374332 |
| SN-032 | CdKs 2,7,9 and MCL-1 | 22966018 | ||
| Sorafenib | B-RAF, PDGF, FLT, KIT, VEGF and Mcl-1 | 22698419 | ||
| Deubiquitinase inhibitor 78 | WP1130 | Bcr-Abl compartmentalization, inhibits USP9X (stabilize Mcl-1) | Pre-clinical | 17202319 |
| Antisense inhibitors | Oblimersen sodium | Bcl-2 | Phase III | 19738118 |
| BH3 mimetics | ABT-737 (AB-263) | Bcl-2, Bcl-XL, Bcl-w | Clinical trials | 22821746 |
| Gossypol (AT-101) | Bcl-2, Bcl-XL, Bcl-w, Mcl-1 | 21918390 | ||
| Apogossypol (ApoG2) | Bcl-2, Bcl-XL, Mcl-1 | 18769131 | ||
| Obatoclax (GX-15-070) | Bcl-2, Bcl-XL, Bcl-w, Mcl-1 Bcl-2 |
22333598 | ||
| HA-14 | Bcl-XL | 19228717 | ||
| BH3Is | Bcl-2, Bcl-XL, Mcl-1 | 16951185 | ||
| TW-37 | Bcl-2, Bcl-XL, Mcl-1, Bfl-1 | 21780116 | ||
| Sabutoclax (BI-97C1) | Bcl-2, Bcl-XL, Mcl-1, Bfl-1 | Preclinical | 22655238 | |
| BI-97D6 | Bcl-2, Bcl-XL, Mcl-1 | 22931411 22655238 |
||
| BH-3 M6 | Bcl-2, Bcl-XL, Mcl-1 | 21148306 |
Abbreviations: CdK- cyclin-dependent kinase; PDGF: platelet derived growth factor; VEGF-Vascular endothelial growth factor